{{Drugbox
| IUPAC_name = Methyl (2''S'')-2-{[1-(cyclohexylmethyl)-1''H''-indazol-3-yl]formamido}-3,3-dimethylbutanoate
| image = MDMB-CHMINACA.svg

<!--Clinical data-->
| tradename = 
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category = 
| legal_AU =
| legal_CA = Schedule II
| legal_UK =
| legal_US =
| legal_status = Illegal in Singapore and Switzerland
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 1185888-32-7
| ATC_prefix =
| ATC_suffix = 
| PubChem = 121491808
| ChemSpiderID      = 32055574
| smiles            = CC(C)(C)[C@@H](C(=O)OC)NC(=O)C1=NN(C2=CC=CC=C21)CC3CCCCC3
| StdInChI          = 1S/C22H31N3O3/c1-22(2,3)19(21(27)28-4)23-20(26)18-16-12-8-9-13-17(16)25(24-18)14-15-10-6-5-7-11-15/h8-9,12-13,15,19H,5-7,10-11,14H2,1-4H3,(H,23,26)/t19-/m1/s1
| StdInChIKey       = DGQMLBSSRFFINY-LJQANCHMSA-N

<!--Chemical data-->
| C=22 | H=31 | N=3 | O=3
| molecular_weight = 
}}

'''MDMB-CHMINACA''' (also known as '''MDMB(N)-CHM''') is an [[indazole]]-based [[synthetic cannabinoid]] that acts as a potent [[agonist]] of the [[Cannabinoid receptor type 1|CB<sub>1</sub> receptor]],<ref>{{cite journal|first1=Samuel D.|last1=Banister|first2=Mitchell|last2=Longworth|first3=Richard|last3=Kevin|first4=Shivani|last4=Sachdev|title=Pharmacology of Valinate and ''tert''-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues|url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00137|journal=ACS Chemical Neuroscience|date=2016|doi=10.1021/acschemneuro.6b00137|pmid=27421060|first5=Marina|last5=Santiago|first6=Jordyn|last6=Stuart|first7=James B. C.|last7=Mack|first8=Michelle|last8=Glass|first9=Iain S.|last9=McGregor|first10=Mark|last10=Connor|first11=Michael|last11=Kassiou|volume=7|pages=1241–54}}</ref> and has been sold online as a [[designer drug]].<ref>{{cite web | url=https://www.caymanchem.com/Product.vm/catalog/16200 | title=MDMB-CHMINACA | publisher=Cayman Chemical | accessdate=14 July 2015}}</ref><ref>{{cite journal|first1=Vadim|last1=Shevyrin|first2=Vladimir|last2=Melkozerov|first3=Alexander|last3=Nevero|first4=Oleg|last4=Eltsov|title=Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a ''N''-1-methoxycarbonylalkyl group|url=https://link.springer.com/article/10.1007/s00216-015-8612-7|journal=Analytical and Bioanalytical Chemistry|date=August 2015|issn=1618-2642|pages=6301–6315|volume=407|issue=21|doi=10.1007/s00216-015-8612-7|first5=Yuri|last5=Shafran|first6=Yuri|last6=Morzherin|first7=AlbertT.|last7=Lebedev|pmid=25893797}}</ref><ref>{{cite web | url=http://www.nncn.ru/objects/nncn01/1406569417.pdf | title=Detection methods of psychoactive substances and liquid chromotograoghy detection of metabolites. | publisher=Russian Ministry of Health | date=2014 | accessdate=14 July 2015 | author=Prof. SA Savchuk | language=ru}}</ref><ref>{{cite web | url=http://scientific-technology.ru/khromatomass-spektrometriya/obnaruzhenie-i-identifikatsiya-sinteticheskikh-kannabimimetikov/166-identifikatsiya-sinteticheskikh-kannabimimetikov-mdmb-chminaca-mdmb-fubinaca-i-ikh-metabolitabolitov-2 | title=Идентификация синтетических каннабимиметиков MDMB-CHMINACA, MDMB-FUBINACA и их метаболитов | publisher=CTS "SCIENCE" | accessdate=14 July 2015| language=ru}}</ref><ref>{{cite journal|first1=Cornelius|last1=Hess|first2=Jacqueline|last2=Murach|first3=Lynn|last3=Krueger|first4=Lisa|last4=Scharrenbroch|title=Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples|url=http://onlinelibrary.wiley.com/doi/10.1002/dta.2030/abstract|journal=Drug Testing and Analysis|date=2016|issn=1942-7611|doi=10.1002/dta.2030|pmid=27400642|first5=Michael|last5=Unger|first6=Burkhard|last6=Madea|first7=Konrad|last7=Sydow}}</ref> It was invented by [[Pfizer]] in 2008, and is one of the most potent cannabinoid agonists known, with a [[Affinity (pharmacology)#Protein-ligand binding|binding affinity]] of 0.0944 nM at [[Cannabinoid receptor type 1|CB<sub>1</sub>]], and an EC<sub>50</sub> of 0.330 nM.<ref>[http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009106980 Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106980]</ref> It is closely related to [[MDMB-FUBINACA]], which caused at least 1000 hospitalizations and 40 deaths in Russia as consequence of intoxication.<ref>{{cite web | url=http://www.fskn.gov.ru/includes/periodics/news/2015/0317/205035975/detail.shtml | title=Очередная жертва спайса | publisher=Federal Drug Control Service of the Russian Federation | date=17 March 2015 | accessdate=13 July 2015| language=ru}}</ref>

==Legal status==
MDMB-CHMINACA is a Fifth Schedule of the Misuse of Drugs Act (MDA) controlled substance in Singapore as of May 2015.<ref>{{cite web | url=http://www.cnb.gov.sg/Libraries/CNB_Newsroom_Files/CNB_NR_-_30_Apr_2015.sflb.ashx | title=CNB NEWS RELEASE | publisher=Central Narcotics Bureau (CNB) | date=30 April 2015 | accessdate=14 July 2015}}</ref>

MDMB-CHMINACA is illegal in Switzerland as of December 2015.<ref>{{cite web | url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html | title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien | publisher=Der Bundesrat|language=de}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[AB-CHMINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[MDMB-CHMICA]]
* [[MDMB-FUBINACA]]
* [[PX-3]] (APP-CHMINACA)
{{Div col end}}

==References==
{{Reflist}}

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazolecarboxamides]]


{{cannabinoid-stub}}